---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-216321"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:39:06.607080+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viridian's veligrotug Phase 3 THRIVE meets all endpoints; 70% proptosis responder rate vs 5% placebo (p<0.0001)

## Summary
- Proptosis responder rate 70% drug vs 5% placebo; mean reduction 2.9 mm vs 0.5 mm (p<0.0001).
- Complete diplopia resolution 54% vs 12%; CAS 0/1 achieved by 64% vs 18% (both p<0.0001).
- No treatment-related serious AEs; 5.5% placebo-adjusted hearing impairment rate; 4% discontinuation rate.
- THRIVE-2 enrollment complete; topline data year-end 2024; BLA submission on track for 2H 2025.
- Cash $571.4M as of June 30, 2024; runway into 2H 2026; VRDN-003 phase 3 REVEAL trials initiated.

## SEC filing metadata
- accession: 0001193125-24-216321
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524216321/0001193125-24-216321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524216321/d885072d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-216321
- JSON: https://secwatch.observer/filing/0001193125-24-216321.json
- Plain text: https://secwatch.observer/filing/0001193125-24-216321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.